Search results
Showing 1951 to 2000 of 2008 results for news
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
The first in a new class of treatment to be recommended by NICE for treating acute migraine will soon be available on the NHS to around 13,000 people.
Home News Podcasts Navigating the future - AI at NICE Podcasts 28 February 2025 Listen About this episode Dr Pall Jonsson, programme...
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE recommends olaparib for early breast cancer and metastatic prostate cancer
Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
Seven technologies recommended to help people with non-specific low back pain
People with non-specific low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended in draft guidance.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use
Draft guidance for the potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
An insight into one of NICE’s most long-standing collaborative relationships.
NICE guidance addresses the best approach to the diagnosis and management of ME/CFS
NICE has today (10 November 2020) published its draft guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
Aortic valve reconstruction with processed bovine pericardium (HTG461)
Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.
View recommendations for HTG461Show all sections
Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.
View recommendations for HTG470Show all sections
New treatment for cardiovascular disease could benefit millions
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
Updated guideline recommends more treatment choices for menopause symptoms
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation
NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.
How NICE is helping to build the role of the NHS on the global stage
Kevin Miles discusses how NICE International is working to shape and improve health and care systems at home and abroad as part of the NHS Consortium for Global Health.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
New life-changing treatment option recommended for type of rare epilepsy
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.
Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're...
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Learn more about the NICE and NHS England MedTech Pathway consultation
Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode
Endometriosis - learn more about NICE's guideline for this chronic condition
Home News Podcasts Endometriosis - learn more about NICE's guideline for this chronic condition Podcasts 25 March 2025 Listen About this...
Children and young people need accurate, accessible information about their healthcare
New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
New treatment option for adults with obesity and non-diabetic hyperglycaemia
All eligibility criteria must be met for Liraglutide to be offered.
Home testing devices could increase the number of people diagnosed with sleep apnoea
Five home-testing devices to diagnose a silent sleep condition harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.
New NICE quality standard identifies improvements in UTI diagnosis for women
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.
Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS.
Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for HTG279Show all sections
Sections for HTG279
Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.
NICE recommends digital technology to help diagnose ADHD in children and young people
A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.
Thousands of appointments released for the NHS without compromising safety
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%
Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.